probucol has been researched along with Apolipoprotein B-100, Familial Defective in 94 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to compare the effects of lovastatin and probucol on lipoprotein profiles, we treated 32 familial hypercholesterolemia (FH) heterozygotes and 26 patients with non-familial hypercholesterolemia for 14 weeks with either probucol (1 g/d) or lovastatin (40-80 mg/d) in a randomized double-blind study." | 9.06 | Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. ( Helve, E; Tikkanen, MJ, 1988) |
| "Long-term effects of pravastatin and probucol on serum cholesteryl ester transfer protein (CETP) and xanthoma/xanthelasma size were compared." | 7.70 | Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. ( Chichibu, K; Inazu, A; Kajinami, K; Kiyohar, T; Koizumi, J; Mabuchi, H, 1999) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 7.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels." | 6.36 | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982) |
| "A 66-year-old male heterozygous familial hypercholesterolemia (FH) patient with significant coronary atherosclerosis has been treated by us with probucol (1000 mg daily) for eight years." | 5.29 | Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. ( Kajinami, K; Koizumi, J; Mabuchi, H; Nishitsuji, M; Shimizu, M; Takeda, Y, 1996) |
| "The lovastatin-alone regimen was well tolerated, whereas addition of colestipol caused subjective side effects in many patients." | 5.28 | Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. ( Helve, E; Karjalainen, K; Ojala, JP; Tarkkanen, A; Tikkanen, MJ, 1990) |
| "The family members had episodes of cerebral infarction and apparently had atherosclerosis of the internal carotid artery, but no coronary heart disease due to their almost normal level of cholesterol." | 5.28 | A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate. ( Fujita, H; Ihara, Y; Kajinami, K; Kamisaka, K; Kibata, M; Mabuchi, H; Namba, R; Nobukuni, K; Ohshima, K; Shirabe, T, 1991) |
| "Fifty-one patients with familial hypercholesterolemia were treated for 2 to 4 years with probucol, cholestyramine, clofibrate and compactin in various combinations." | 5.27 | Effects of probucol on xanthomata regression in familial hypercholesterolemia. ( Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S, 1986) |
| "In order to compare the effects of lovastatin and probucol on lipoprotein profiles, we treated 32 familial hypercholesterolemia (FH) heterozygotes and 26 patients with non-familial hypercholesterolemia for 14 weeks with either probucol (1 g/d) or lovastatin (40-80 mg/d) in a randomized double-blind study." | 5.06 | Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. ( Helve, E; Tikkanen, MJ, 1988) |
| "Probucol is known to prolong QT intervals in some patients and to produce fatal arrhythmias in selected animal species." | 5.05 | Electrocardiographic effects of probucol. A controlled prospective clinical trial. ( Atkins, F; Chernoff, SB; DeCoursey, S; Dujovne, CA; Krehbiel, P; Wong, B, 1984) |
| "Long-term effects of pravastatin and probucol on serum cholesteryl ester transfer protein (CETP) and xanthoma/xanthelasma size were compared." | 3.70 | Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. ( Chichibu, K; Inazu, A; Kajinami, K; Kiyohar, T; Koizumi, J; Mabuchi, H, 1999) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 3.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Patients with familial hypercholesterolemia (FH) have had a life-long sustained elevation of low-density lipoprotein (LDL) cholesterol levels." | 2.66 | Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. ( Beltz, WF; Juliano, J; Kelly, N; Lester, P; Simmons, D; Steinberg, D; Weinreb, R; Witztum, JL; Young, SG, 1989) |
| "Probucol is a potent anti-oxidant drug that has been in clinical use during the past few decades for the treatment and prevention of cardiovascular diseases." | 2.45 | Where are we with probucol: a new life for an old drug? ( Matsuzawa, Y; Yamashita, S, 2009) |
| "In heterozygous familial hypercholesterolemia, probucol lowered total cholesterol levels by 22%, LDL-cholesterol levels by 17%, and HDL-cholesterol levels by 40%, respectively." | 2.39 | [Probucol treatment of hyperlipidemia]. ( Koizumi, J, 1994) |
| "Probucol is a lipid-regulating agent structurally dissimilar to other known agents, with a unique pharmacodynamic and clinical profile." | 2.38 | Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. ( Brogden, RN; Buckley, MM; Goa, KL; Price, AH, 1989) |
| "The surgical treatment of hypercholesterolemia and the treatment of homozygous and other forms of hypercholesterolemia are also detailed." | 2.36 | Treatment of hypercholesterolemia. ( Kane, JP; Malloy, MJ, 1982) |
| "Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels." | 2.36 | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982) |
| "Regarding patients with familial hypercholesterolemia, those treated with probucol, which is a potent anti-oxidative and anti-hyperlipidemic drug, showed significantly lower Ox-HDL (16." | 1.62 | Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein. ( Inui, H; Kanno, K; Katayama, Y; Koseki, M; Masuda, D; Nishida, M; Ohama, T; Okada, T; Saga, A; Sakata, Y; Sumida, M; Yamashita, S, 2021) |
| "Probucol is a lipid-lowering drug that is often prescribed for the treatment of familial hypercholesterolemia." | 1.40 | Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits. ( Bilal Waqar, A; Fan, J; Kang, D; Koike, T; Li, S; Liang, J; Niimi, M; Shiomi, M; Wang, Y, 2014) |
| "Moreover, middle-aged familial hypercholesterolemia (FH) subjects show a particularly high incidence of mild cognitive impairments (MCI)." | 1.39 | Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia. ( Aguiar, AS; de Bem, AF; de Carvalho, CR; de Oliveira, J; Farina, M; Moreira, EL; Prediger, RD; Santos, DB; Walz, R; Xikota, JC, 2013) |
| "Probucol-treated FH patients (n=21) showed a 47% reduction of serum HDL-C levels compared to probucol-untreated FH patients (n=15)." | 1.38 | Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. ( Inagaki, M; Ishigami, M; Kawase, M; Kawase, R; Komuro, I; Masuda, D; Matsuyama, A; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Tsubakio-Yamamoto, K; Yamashita, S, 2012) |
| "Homozygous familial hypercholesterolemia is a rare hypercholesterolemia representing 1 to 2% of hypercholesterolemia." | 1.35 | [Coronary artery bypass graft in adolescent suffering from homozygous familial hypercholesterolemia resistant to probucol therapy]. ( Ahmed-Nasr, M; Ayegnon, KG; Morcos, KK; Yangni-Angate, KH, 2009) |
| "A 66-year-old male heterozygous familial hypercholesterolemia (FH) patient with significant coronary atherosclerosis has been treated by us with probucol (1000 mg daily) for eight years." | 1.29 | Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. ( Kajinami, K; Koizumi, J; Mabuchi, H; Nishitsuji, M; Shimizu, M; Takeda, Y, 1996) |
| "Fifty-seven patients with familial hypercholesterolemia (FH) with mean age of 48 years (range 30 to 69), participated in a follow-up examination 5." | 1.29 | Results of intensive long-term treatment of familial hypercholesterolemia. ( Gørbitz, C; Ose, L; Retterstøl, K; Stugaard, M, 1996) |
| "Probucol was administered in a dosage of 500 mg twice daily for 3 months." | 1.28 | Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoprotein E4. ( Eto, M; Iwashima, Y; Makino, I; Sato, T; Watanabe, K, 1990) |
| "Probucol treatment for this period caused significant reductions in the serum levels of total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol, and apoprotein AI, AII, B, and CIII in both groups." | 1.28 | Effects of long-term treatment with probucol on serum lipoproteins in cases of familial hypercholesterolemia in the elderly. ( Ishikawa, Y; Kobayashi, J; Mori, S; Morisaki, N; Saito, Y; Shinomiya, M; Shirai, K; Yoshida, S, 1990) |
| "The lovastatin-alone regimen was well tolerated, whereas addition of colestipol caused subjective side effects in many patients." | 1.28 | Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. ( Helve, E; Karjalainen, K; Ojala, JP; Tarkkanen, A; Tikkanen, MJ, 1990) |
| "The family members had episodes of cerebral infarction and apparently had atherosclerosis of the internal carotid artery, but no coronary heart disease due to their almost normal level of cholesterol." | 1.28 | A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate. ( Fujita, H; Ihara, Y; Kajinami, K; Kamisaka, K; Kibata, M; Mabuchi, H; Namba, R; Nobukuni, K; Ohshima, K; Shirabe, T, 1991) |
| "Seventeen patients with heterozygous familial hypercholesterolemia were sequentially treated with: a low cholesterol, fat restricted diet; diet and probucol (500 mg/day); and diet, probucol and niceritrol (1500 mg/day)." | 1.28 | New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia. ( Fukushima, N; Ozaki, I; Sakai, T; Setoguchi, Y; Yamamoto, K; Yanagita, T, 1991) |
| "Treatment with probucol resulted in the regression of cutaneous and tendon xanthomas." | 1.27 | Effects of probucol on homozygous cases of familial hypercholesterolemia. ( Hayashi, R; Hirobe, K; Kikkawa, T; Kishino, B; Matsuzawa, Y; Yamamoto, A, 1983) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Probucol has been shown to be an effective and well-tolerated cholesterol-lowering drug." | 1.27 | Apolipoprotein E polymorphism and plasma cholesterol response to probucol. ( Bouthillier, D; Davignon, J; Nestruck, AC; Sing, CF, 1987) |
| "Probucol is a drug that lowers both LDL and HDL cholesterol levels." | 1.27 | Lipoprotein fractions and receptors: a role for probucol? ( Bilheimer, DW, 1986) |
| "Probucol is a drug with hypolipidemic effect from the group of diphenols." | 1.27 | [Clinical research on the hypolipidemic action of a probucol preparation]. ( Balabanski, L; Goranov, I; Kerekovska, M; Naumova, R, 1986) |
| "Fifty-one patients with familial hypercholesterolemia were treated for 2 to 4 years with probucol, cholestyramine, clofibrate and compactin in various combinations." | 1.27 | Effects of probucol on xanthomata regression in familial hypercholesterolemia. ( Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S, 1986) |
| "Achilles tendon xanthoma diminished significantly." | 1.27 | Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange. ( Adolph, R; Glueck, CJ; Rice, V; Spitz, HB; Stein, EA, 1986) |
| "Subjects with heterozygous familial hypercholesterolemia on probucol had a significant 31% reduction in mononuclear cell sterol synthesis rates as compared to control patients; sterol synthesis in cells from homozygous familial hypercholesterolemic patients on probucol did not differ from that in control subjects." | 1.27 | Sterol synthesis in vitro in freshly isolated blood mononuclear leukocytes from familial hypercholesterolemic patients treated with probucol. ( Bloch, CA; Botha, A; McNamara, DJ; Mendelsohn, D, 1985) |
| "Oral carnitine has been reported to have a lipid-lowering effect with concomitant elevation of high density lipoprotein cholesterol (HDL-C) levels in normo- and hyperlipidemic individuals." | 1.27 | Plasma carnitine and lipid-lowering drugs. ( Davignon, J; Nestruck, AC; Pande, SV, 1985) |
| "Probucol was almost entirely removed by lipoproteins; 75% of the drug was found in LDL, the remainder being equally distributed in VLDL and HDL." | 1.27 | The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia. ( Buxtorf, JC; Dachet, C; Jacotot, B, 1985) |
| "during 6 months." | 1.26 | [Effects of probucol on skin cholesterol concentrations in patients with type II hyperlipoproteineamia (author's transl)]. ( Beaumont, JL; Beaumont, V; Buxtorf, JC; Jacotot, B; Meliço-Silvestre, AA, 1980) |
| "probucol is a new hypolipaemic agent which differs from similar drugs in current use by its chemical structurae and, probably, by its mode of action." | 1.26 | [The effects of probucol in man (author's transl)]. ( Leutenegger, M, 1980) |
| "Tendon xanthomas were present in 11 and xanthelasma in 4." | 1.26 | Effects of probucol on the cholesterol content of skin in type II hyperlipoproteinemias. ( Beaumont, JL; Beaumont, V; Buxtorf, JC; Jacotot, B; Silvestre, M, 1982) |
| "Probucol was well tolerated by child and adult patients." | 1.26 | Treatment of homozygous familial hypercholesterolaemia with probucol. ( Baker, SG; Joffe, BI; Mendelsohn, D; Seftel, HC, 1982) |
| "Probucol was administered for 4 months in 20 adult males with Type IIb HLP in a total daily dose of 1." | 1.26 | Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia. ( Bell, C; Hunninghake, DB; Olson, L, 1980) |
| "Probucol was used to treat 16 patients with atherogenic hyperlipoproteinaemia." | 1.26 | [Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)]. ( Bakir, R; Chanu, B; Goy-Loepper, J; Rouffy, J; Saya, C, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 60 (63.83) | 18.7374 |
| 1990's | 24 (25.53) | 18.2507 |
| 2000's | 4 (4.26) | 29.6817 |
| 2010's | 4 (4.26) | 24.3611 |
| 2020's | 2 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Mao, SJ | 1 |
| Yates, MT | 1 |
| Rechtin, AE | 1 |
| Jackson, RL | 1 |
| Van Sickle, WA | 1 |
| Okada, T | 1 |
| Sumida, M | 1 |
| Ohama, T | 2 |
| Katayama, Y | 1 |
| Saga, A | 1 |
| Inui, H | 1 |
| Kanno, K | 1 |
| Masuda, D | 3 |
| Koseki, M | 1 |
| Nishida, M | 2 |
| Sakata, Y | 1 |
| Yamashita, S | 7 |
| Harada-Shiba, M | 2 |
| Arai, H | 1 |
| Bujo, H | 1 |
| Ishibashi, S | 1 |
| Daida, H | 1 |
| Koga, N | 2 |
| Oikawa, S | 2 |
| Moreira, EL | 1 |
| Aguiar, AS | 1 |
| de Carvalho, CR | 1 |
| Santos, DB | 1 |
| de Oliveira, J | 1 |
| de Bem, AF | 1 |
| Xikota, JC | 1 |
| Walz, R | 1 |
| Farina, M | 1 |
| Prediger, RD | 1 |
| Li, S | 1 |
| Liang, J | 1 |
| Niimi, M | 1 |
| Bilal Waqar, A | 1 |
| Kang, D | 1 |
| Koike, T | 1 |
| Wang, Y | 1 |
| Shiomi, M | 1 |
| Fan, J | 1 |
| Lin, M | 1 |
| Dai, H | 1 |
| Zhao, S | 1 |
| Matsuzawa, Y | 6 |
| Ayegnon, KG | 1 |
| Morcos, KK | 1 |
| Yangni-Angate, KH | 1 |
| Ahmed-Nasr, M | 1 |
| Inagaki, M | 2 |
| Nakagawa-Toyama, Y | 1 |
| Nakatani, K | 1 |
| Nakaoka, H | 1 |
| Kawase, M | 1 |
| Kawase, R | 1 |
| Tsubakio-Yamamoto, K | 1 |
| Matsuyama, A | 1 |
| Ishigami, M | 1 |
| Komuro, I | 1 |
| Saito, M | 1 |
| Tada, Y | 1 |
| Yamamoto, A | 4 |
| Kusakabe, N | 1 |
| Yokogawa, M | 1 |
| Kodama, H | 1 |
| Asada, H | 1 |
| Miyagawa, S | 1 |
| Mann, JI | 2 |
| Jelfs, R | 1 |
| Cassels, E | 1 |
| Barker, K | 1 |
| Simpson, HC | 2 |
| Carter, RC | 1 |
| Pasquali, R | 2 |
| Biso, P | 2 |
| Parenti, M | 2 |
| Melchionda, N | 2 |
| Bradlow, BA | 1 |
| Chetty, N | 1 |
| Birnbaum, M | 1 |
| Baker, SG | 2 |
| Seftel, HC | 2 |
| Dujovne, CA | 3 |
| Krehbiel, P | 3 |
| Decoursey, S | 2 |
| Jackson, B | 1 |
| Chernoff, SB | 3 |
| Pitterman, A | 1 |
| Garty, M | 1 |
| Atkins, F | 1 |
| Wong, B | 1 |
| Jones, DB | 1 |
| Slaughter, P | 1 |
| Lousley, S | 1 |
| Carter, RD | 1 |
| Cobbe, SM | 1 |
| Markiewicz, M | 1 |
| Rymar, B | 1 |
| Horubała-Bielak, G | 1 |
| Koziara, Z | 1 |
| Kishino, B | 3 |
| Hayashi, R | 1 |
| Hirobe, K | 1 |
| Kikkawa, T | 1 |
| Kawecka-Jaszcz, K | 1 |
| Kocemba, J | 1 |
| Wasowicz, B | 1 |
| Król, W | 1 |
| Atmeh, RF | 1 |
| Stewart, JM | 1 |
| Boag, DE | 1 |
| Packard, CJ | 1 |
| Lorimer, AR | 1 |
| Shepherd, J | 1 |
| Mellies, MJ | 1 |
| Gartside, PS | 1 |
| Glatfelter, L | 1 |
| Vink, P | 1 |
| Guy, G | 1 |
| Schonfeld, G | 1 |
| Glueck, CJ | 3 |
| Kane, JP | 2 |
| Malloy, MJ | 1 |
| Dauignon, J | 1 |
| Bouthillier, D | 2 |
| Joffe, BI | 1 |
| Mendelsohn, D | 2 |
| Beaumont, JL | 3 |
| Jacotot, B | 6 |
| Buxtorf, JC | 4 |
| Silvestre, M | 1 |
| Beaumont, V | 4 |
| Jirsa, M | 2 |
| Marecek, Z | 2 |
| Kerdac, V | 1 |
| Kucerova, L | 1 |
| Cortese, C | 1 |
| Marenah, CB | 1 |
| Miller, NE | 1 |
| Lewis, B | 1 |
| Cavazzini, MG | 1 |
| Baraldi, G | 1 |
| Sorrenti, G | 1 |
| De Benedittis, G | 1 |
| Labò, G | 1 |
| Sznajderman, M | 2 |
| Kuczyńska, K | 1 |
| Gagné, C | 1 |
| Lupien, PJ | 1 |
| Brun, D | 1 |
| Moorjani, S | 1 |
| Toussaint, M | 1 |
| Kordac, V | 1 |
| Kucerová, K | 1 |
| Leutenegger, M | 1 |
| Meliço-Silvestre, AA | 1 |
| Rouffy, J | 1 |
| Chanu, B | 1 |
| Bakir, R | 1 |
| Goy-Loepper, J | 1 |
| Saya, C | 1 |
| Mc Caughan, D | 1 |
| Hunninghake, DB | 1 |
| Bell, C | 1 |
| Olson, L | 1 |
| Braesen, JH | 1 |
| Beisiegel, U | 1 |
| Niendorf, A | 1 |
| Koizumi, J | 3 |
| Tanno, N | 1 |
| Koizumi, M | 1 |
| Kotake, H | 1 |
| Hirakawa, H | 1 |
| Kanazawa, Y | 1 |
| Toyota, T | 1 |
| Feher, MD | 1 |
| Webb, JC | 1 |
| Patel, DD | 1 |
| Lant, AF | 1 |
| Mayne, PD | 1 |
| Knight, BL | 1 |
| Soutar, AK | 1 |
| Homma, Y | 1 |
| Kobayashi, T | 1 |
| Yamaguchi, H | 1 |
| Sakane, H | 1 |
| Ozawa, H | 1 |
| Matsuda, M | 1 |
| Mikami, Y | 2 |
| Nakamura, H | 1 |
| Kajinami, K | 3 |
| Nishitsuji, M | 1 |
| Takeda, Y | 1 |
| Shimizu, M | 1 |
| Mabuchi, H | 3 |
| Tomochika, Y | 1 |
| Okuda, F | 1 |
| Tanaka, N | 1 |
| Wasaki, Y | 1 |
| Tokisawa, I | 1 |
| Aoyagi, S | 1 |
| Morikuni, C | 1 |
| Ono, S | 1 |
| Okada, K | 1 |
| Matsuzaki, M | 1 |
| Retterstøl, K | 1 |
| Stugaard, M | 1 |
| Gørbitz, C | 1 |
| Ose, L | 1 |
| Fukuzawa, S | 1 |
| Ozawa, S | 1 |
| Morooka, S | 1 |
| Inoue, T | 1 |
| Inazu, A | 1 |
| Kiyohar, T | 1 |
| Chichibu, K | 1 |
| Adlouni, A | 1 |
| El Messal, M | 1 |
| Saïle, R | 1 |
| Parra, H | 1 |
| Fruchart, J | 1 |
| Ghalim, N | 1 |
| Makino, I | 2 |
| Nakamura, T | 1 |
| Ueyama, Y | 1 |
| Funahashi, T | 3 |
| Takemura, KK | 1 |
| Kubo, M | 1 |
| Yamada, K | 1 |
| Tatami, R | 1 |
| Inoue, N | 1 |
| Itoh, H | 1 |
| Nakashima, Y | 1 |
| Nishide, T | 1 |
| Okamura, K | 1 |
| Saito, Y | 3 |
| Teramoto, T | 1 |
| Ihara, Y | 1 |
| Nobukuni, K | 1 |
| Namba, R | 1 |
| Kamisaka, K | 1 |
| Kibata, M | 1 |
| Fujita, H | 1 |
| Shirabe, T | 1 |
| Ohshima, K | 1 |
| Liu, K | 1 |
| Lankin, VZ | 1 |
| Lupanov, VP | 1 |
| Liakishev, AA | 1 |
| Revenko, VM | 1 |
| Franceschini, G | 2 |
| Chiesa, G | 1 |
| Sirtori, CR | 2 |
| Montero Brens, C | 1 |
| Breto Gilabert, M | 1 |
| Dalmau Serra, J | 1 |
| Yamamoto, K | 1 |
| Fukushima, N | 1 |
| Ozaki, I | 1 |
| Setoguchi, Y | 1 |
| Yanagita, T | 1 |
| Sakai, T | 1 |
| Nakai, T | 1 |
| Matsuda, T | 2 |
| Takai, H | 1 |
| Maeda, H | 1 |
| Takahashi, S | 1 |
| Oida, K | 1 |
| Tamai, T | 1 |
| Miyaho, S | 1 |
| Morikawa, K | 1 |
| Kurota, M | 1 |
| Eto, M | 1 |
| Sato, T | 1 |
| Watanabe, K | 1 |
| Iwashima, Y | 1 |
| Morisaki, N | 1 |
| Mori, S | 1 |
| Kobayashi, J | 1 |
| Ishikawa, Y | 1 |
| Shinomiya, M | 1 |
| Shirai, K | 1 |
| Yoshida, S | 2 |
| Ojala, JP | 1 |
| Helve, E | 3 |
| Karjalainen, K | 1 |
| Tarkkanen, A | 1 |
| Tikkanen, MJ | 4 |
| Witztum, JL | 1 |
| Simmons, D | 1 |
| Steinberg, D | 1 |
| Beltz, WF | 1 |
| Weinreb, R | 1 |
| Young, SG | 1 |
| Lester, P | 1 |
| Kelly, N | 1 |
| Juliano, J | 1 |
| Buckley, MM | 1 |
| Goa, KL | 1 |
| Price, AH | 1 |
| Brogden, RN | 1 |
| Fellin, R | 1 |
| Gasparotto, A | 1 |
| Valerio, G | 1 |
| Baiocchi, MR | 1 |
| Padrini, R | 1 |
| Lamon, S | 1 |
| Vitale, E | 1 |
| Baggio, G | 1 |
| Crepaldi, G | 1 |
| Dachet, C | 3 |
| Motta, C | 1 |
| Neufcour, D | 1 |
| Sanjurjo, P | 1 |
| Martul, P | 1 |
| Sasieta, M | 1 |
| Lafuente, P | 1 |
| Ariza, F | 1 |
| Cabeza, I | 1 |
| Sirtori, M | 1 |
| Calabresi, L | 1 |
| Nikkilä, EA | 2 |
| Tarui, S | 1 |
| Davignon, J | 3 |
| Kita, T | 1 |
| Nagano, Y | 1 |
| Yokode, M | 1 |
| Ishii, K | 1 |
| Kume, N | 1 |
| Ooshima, A | 1 |
| Yoshida, H | 1 |
| Kawai, C | 1 |
| Havel, RJ | 1 |
| Gotto, AM | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| Kuo, PT | 1 |
| Wilson, AC | 1 |
| Kostis, JB | 1 |
| Moreyra, AE | 1 |
| Edouard, L | 1 |
| Doucet, F | 1 |
| Carcone, B | 1 |
| Goranov, I | 2 |
| Naumova, R | 2 |
| Kerekovska, M | 2 |
| Balabanski, L | 2 |
| Nestruck, AC | 2 |
| Sing, CF | 1 |
| Bilheimer, DW | 1 |
| Nakao, S | 1 |
| Ueda, M | 1 |
| Harada, M | 1 |
| Yokoyama, S | 1 |
| Yamamura, T | 1 |
| Baudet, MF | 1 |
| Esteva, O | 1 |
| Schaefer, EJ | 1 |
| Levy, RI | 1 |
| Durrington, PN | 1 |
| Miller, JP | 1 |
| Zawadzki, Z | 1 |
| Stein, EA | 1 |
| Adolph, R | 1 |
| Rice, V | 1 |
| Spitz, HB | 1 |
| McNamara, DJ | 1 |
| Bloch, CA | 1 |
| Botha, A | 1 |
| Pande, SV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Safety and Efficacy of Atorvastatin on Xanthoma in Alagille Syndrome[NCT05488067] | Phase 4 | 10 participants (Anticipated) | Interventional | 2022-03-22 | Recruiting | ||
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for probucol and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Where are we with probucol: a new life for an old drug?
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cardiovascular Agents; Cardiovascular Diseases; Evi | 2009 |
Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.
Topics: Arteriosclerosis; Cholesterol; Colestipol; Drug Therapy, Combination; Humans; Hypercholesterolemia; | 1982 |
Treatment of hypercholesterolemia.
Topics: Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Heterozygote; Homozygote; Humans; Hyper | 1982 |
[Probucol treatment of hyperlipidemia].
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; G | 1994 |
[Advance in drug treatment of primary and familial hypercholesterolemia].
Topics: Animals; Cholestyramine Resin; Drugs, Chinese Herbal; Humans; Hypercholesterolemia; Hyperlipoprotein | 1991 |
[Mechanisms of anti-atherogenic effect of probucol and the prospects of its clinical use].
Topics: Arteriosclerosis; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Drug Evaluation; Humans; Hyperch | 1991 |
Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.
Topics: Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Phenols; Probucol | 1989 |
Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Topics: Arteriosclerosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hype | 1987 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom | 1985 |
17 trials available for probucol and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Probucol with colestipol in the treatment of hypercholesterolemia.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Colestipol; Double-Blind Method; Drug Therapy, Combina | 1984 |
Electrocardiographic effects of probucol. A controlled prospective clinical trial.
Topics: Adult; Arrhythmias, Cardiac; Cholesterol, LDL; Clinical Trials as Topic; Electrocardiography; Humans | 1984 |
A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Clinical T | 1984 |
[Effect of probucol on serum cholesterol concentration in primary hyperlipoproteinemia].
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Clofibrate; Female; Humans; Hyperlipoproteinemia | 1982 |
Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia.
Topics: Adult; Apolipoproteins; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Humans; Hyperlip | 1980 |
[Probucol : comparison of its effect with that of a placebo in hyperlipoproteinemia type II].
Topics: Adult; Aged; Anticoagulants; Cholesterol; Drug Synergism; Female; Humans; Hyperlipoproteinemia Type | 1980 |
[Comparative effects of probucol and placebo on blood cholesterol in patients on long-term treatment (author's transl)].
Topics: Cholesterol; Coronary Disease; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Hyperlipop | 1980 |
Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators.
Topics: Adult; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; C | 1992 |
Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
Topics: Cholesterol; Clinical Trials as Topic; Colestipol; Drug Interactions; Drug Therapy, Combination; Hum | 1989 |
Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles.
Topics: Apolipoproteins; Clinical Trials as Topic; Genetic Carrier Screening; Humans; Hypercholesterolemia; | 1988 |
Treatment with probucol of children with familial hypercholesterolaemia.
Topics: Child; Child, Preschool; Cholesterol; Cholesterol, Dietary; Clinical Trials as Topic; Female; Humans | 1988 |
Changes in high-density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Clinical Trials as Topic; | 1988 |
Controlled studies of the efficacy and safety of combined probucol-colestipol therapy.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Colestipol; Double-Blind Method; Drug | 1986 |
Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Colestipol; | 1986 |
Effects of several lipid-lowering drugs on skin total and esterified cholesterol.
Topics: Cholesterol Esters; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hyp | 1986 |
Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; | 1985 |
[Effect of probucol on lipid and lipoprotein levels and serum apolipoproteins A1 and B in patients with hyperlipoproteinemia type II].
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Clinical Trials as Topic; Fem | 1985 |
66 other studies available for probucol and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cells, Cultured; Cholesterol; Hyperlipoproteinemia | 1991 |
Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
Topics: Adult; Antioxidants; Atherosclerosis; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Huma | 2021 |
Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxy | 2022 |
Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Cognition Disorders; Founder Effect; Hyperlipoproteinemia Type II | 2013 |
Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic | 2014 |
Long-term atorvastatin-ezetimibe-probucol triple therapy for homozygous familial hypercholesterolaemia from early childhood.
Topics: Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Drug Therapy, Combination; Ezetimib | 2016 |
[Coronary artery bypass graft in adolescent suffering from homozygous familial hypercholesterolemia resistant to probucol therapy].
Topics: Adolescent; Anticholesteremic Agents; Coronary Artery Bypass; Drug Resistance; Homozygote; Humans; H | 2009 |
Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Female; Heterozygote; Humans; Hyperl | 2012 |
Homozygous familial hypercholesterolaemia: development of xanthogranuloma in a boy at puberty under long-term low-density lipoprotein apheresis and drug therapy.
Topics: Adolescent; Anticholesteremic Agents; Blood Component Removal; Humans; Hyperlipoproteinemia Type II; | 2003 |
Probucol in patients resistant to the lipid-lowering effects of cholestyramine.
Topics: Adult; Cholestyramine Resin; Humans; Hyperlipoproteinemia Type II; Middle Aged; Phenols; Probucol | 1981 |
Combined effects of probucol and cholestyramine in familial type II hyperlipoproteinaemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Male; | 1981 |
Platelet function in familial hypercholesterolaemia in South Africa and the effects of probucol.
Topics: Adolescent; Adult; Aged; beta-Thromboglobulin; Child; Cholesterol; Coronary Disease; Female; Humans; | 1982 |
[Serum cholesterol and triglyceride levels in patients with type II hyperlipoproteinemia treated with probucol].
Topics: Adolescent; Adult; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Phe | 1984 |
Effects of probucol on homozygous cases of familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol; Energy Intake; Female; Homozygote; Humans; | 1983 |
The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
Topics: Adult; Apolipoproteins; Apolipoproteins A; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; | 1983 |
Probucol and familial hypercholesterolemia.
Topics: Humans; Hyperlipoproteinemia Type II; Phenols; Probucol | 1982 |
Treatment of homozygous familial hypercholesterolaemia with probucol.
Topics: Adolescent; Adult; Angina Pectoris; Child; Cholesterol; Diet; Electrocardiography; Female; Follow-Up | 1982 |
Effects of probucol on the cholesterol content of skin in type II hyperlipoproteinemias.
Topics: Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Male; Phenols; Probucol; Skin; Xanthomato | 1982 |
Effect of probucol on bile composition in man.
Topics: Adult; Bile; Bile Acids and Salts; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lipid | 1982 |
The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diarrhea; Electrocardiogra | 1982 |
[Comparative effect of probucol and clofibrate in patients with primary hypercholesterolemia].
Topics: Adult; Clofibrate; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle | 1982 |
[Effect of probucol on blood lipid level and lecithin acyltransferase activity in type II hyperlipoproteinemia].
Topics: Adult; Aged; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; P | 1981 |
Probucol and high-density-lipoprotein cholesterol.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; | 1980 |
[The effect of probucol of bile composition].
Topics: Adult; Bile; Bile Acids and Salts; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middl | 1981 |
[The effects of probucol in man (author's transl)].
Topics: Anticholesteremic Agents; Arteriosclerosis; Bile; Clofibrate; Electrocardiography; Heart; Humans; Hy | 1980 |
[Effects of probucol on skin cholesterol concentrations in patients with type II hyperlipoproteineamia (author's transl)].
Topics: Adult; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Phenols | 1980 |
[Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
Topics: Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; | 1980 |
Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.
Topics: Adult; Cholesterol; Coronary Disease; Humans; Hyperlipoproteinemia Type II; Hypolipoproteinemias; Li | 1980 |
Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits.
Topics: Animals; Arteriosclerosis; Female; Hyperlipoproteinemia Type II; Male; Probucol; Rabbits | 1995 |
Biliary lipid composition in heterozygous familial hypercholesterolemia and influence of treatment with probucol.
Topics: Adult; Bile; Bile Acids and Salts; Cholesterol; Female; Heterozygote; Humans; Hyperlipoproteinemia T | 1994 |
Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Cholesterol; Female; Homozygote; Humans; Hyperli | 1993 |
Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Glycoproteins; Humans; Hy | 1993 |
Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary A | 1996 |
Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Echocardiograph | 1996 |
Results of intensive long-term treatment of familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atrial Natriuretic Factor; Cholesterol; Cholestyramine Resin; | 1996 |
Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholestyramine Resin; Coronary Arter | 1999 |
Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.
Topics: Achilles Tendon; Adult; Aged; Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer | 1999 |
Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles.
Topics: Adipocytes; Adult; Anticholesteremic Agents; Apolipoprotein A-I; Biological Transport; Carrier Prote | 2000 |
[Diagnosis and treatment of familial hypercholesterolemia].
Topics: Adult; Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hyperlipopro | 1992 |
Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases.
Topics: Adult; Cholesterol; Eyelid Diseases; Humans; Hyperlipoproteinemia Type II; Macrophages; Male; Middle | 1992 |
A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate.
Topics: Arteriosclerosis; Axons; Carpal Tunnel Syndrome; CD4-CD8 Ratio; Cerebral Infarction; Corneal Opacity | 1991 |
Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients.
Topics: Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholest | 1991 |
[The role of apoprotein B in the diagnosis and follow up of hyperlipoproteinemias in childhood].
Topics: Apolipoproteins B; Child; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoprote | 1991 |
New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; | 1991 |
[A case of familial hypercholesterolemia associated with nephrotic syndrome].
Topics: Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinem | 1990 |
Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoprotein E4.
Topics: Apolipoprotein E4; Apolipoproteins E; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoprot | 1990 |
Effects of long-term treatment with probucol on serum lipoproteins in cases of familial hypercholesterolemia in the elderly.
Topics: Administration, Oral; Adult; Aged; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Depression, | 1990 |
Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up.
Topics: Adult; Aged; Cholesterol, LDL; Colestipol; Female; Follow-Up Studies; Humans; Hypercholesterolemia; | 1990 |
[Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Blood Component Removal; Cholesterol; Drug Therapy, Combinati | 1989 |
Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; | 1986 |
Modifications in the chemical composition and thermometric behavior of LDL and HDL by probucol in type IIa hyperlipoproteinemia.
Topics: Adolescent; Adult; Cholesterol Esters; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, H | 1988 |
Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Corneal | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Disease Models, Animal; Female; Hyperlipopr | 1987 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co | 1987 |
[Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
Topics: Bezafibrate; Cholesterol; Drug Evaluation; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemi | 1987 |
Apolipoprotein E polymorphism and plasma cholesterol response to probucol.
Topics: Adult; Alleles; Apolipoproteins E; Cholesterol; Genotype; Humans; Hyperlipoproteinemia Type II; Midd | 1987 |
Lipoprotein fractions and receptors: a role for probucol?
Topics: Anticholesteremic Agents; Biological Transport; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; | 1986 |
[A case of familial hypercholesterolemia associated with Basedow's disease].
Topics: Adult; Graves Disease; Humans; Hyperlipoproteinemia Type II; Male; Probucol; Thyroxine; Triiodothyro | 1987 |
[Clinical research on the hypolipidemic action of a probucol preparation].
Topics: Adult; Cholesterol; Drug Evaluation; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type | 1986 |
Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Child, Preschool; Cholest | 1986 |
Effects of probucol on the composition and in vitro catabolism of LDL in type IIa hypercholesterolemia.
Topics: Adult; Aged; Cells, Cultured; Female; Fibroblasts; Humans; Hyperlipoproteinemia Type II; Lipoprotein | 1986 |
Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange.
Topics: Achilles Tendon; Adult; Angiography; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Coronary D | 1986 |
Sterol synthesis in vitro in freshly isolated blood mononuclear leukocytes from familial hypercholesterolemic patients treated with probucol.
Topics: Cholesterol; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Male; Monocytes; Ph | 1985 |
Plasma carnitine and lipid-lowering drugs.
Topics: Carnitine; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlip | 1985 |
The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia.
Topics: Adult; Aged; Biological Transport, Active; Cholesterol; Cholesterol Esters; Female; Humans; Hyperlip | 1985 |